Biocon Limited has clarified that its committee is still evaluating strategic options for Biocon Biologics Limited (BBL), including a potential merger. This follows recent media reports regarding the potential merger, IPO, and share swap options. Biocon stated that the committee is considering various factors, including legal and tax implications, and will require board and shareholder approvals. The company assures adherence to governance standards and will disclose any material developments as required.
Strategic Review Continues
Biocon Limited addressed recent media speculation regarding the potential merger of Biocon Biologics Limited (BBL), an unlisted subsidiary, with the parent company. The company clarified that a committee is actively evaluating several strategic options. These options also include a potential IPO and share swap.
Committee’s Ongoing Evaluation
As stated in the press release dated May 8, 2025, the committee is weighing options for restructuring, including the merger of BBL and Biocon. The company is currently evaluating matters related to legal and tax aspects. All decisions are subject to approvals from the Board, shareholders, and regulatory bodies.
No Disclosable Event Yet
Biocon stated that there is currently no material event or information requiring disclosure. The company commits to upholding high governance standards and making disclosures in compliance with applicable laws as and when needed. The committee will continue to evaluate the best value creation option for the company.
Source: BSE